Enhancing the Anti-Tumor Effects of Cancer Peptide Vaccine Therapy
Norihiro Fujinami, Yu Sawada, Daisuke Nobuoka1 and Tetsuya Nakatsura*
Division of Cancer Immunotherapy, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan
- *Corresponding Author:
- Tetsuya Nakatsura
Division of Cancer Immunotherapy
Exploratory Oncology Research & Clinical Trial Center
National Cancer Center, Kashiwa, Chiba, Japan
E-mail: [email protected]
Received date: July 13, 2016; Accepted date: July 25, 2016; Published date: July 28, 2016
Citation: Fujinami N, Sawada Y, Nobuoka D, Nakatsura T (2016) Enhancing the Anti-Tumor Effects of Cancer Peptide Vaccine Therapy. J Vaccines Vaccin 7:330. doi: 10.4172/2157-7560.1000330
Copyright: © 2016 Fujinami N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The clinical efficacy of cancer peptide vaccines has been considered inadequate. To enhance the anti-tumor effects of peptide vaccines, we have studied effective enhancement methods for peptide vaccine therapies such as intratumoral peptide injection and combination therapies with anti-PD-1 blocking antibody or anti-CD4 depletion antibody. We aim to present effective clinical applications of peptide vaccines.